Pluri Inc.
PLURNASDAQHealthcareBiotechnology
Previous close
$1.71
−$0.06 · -3.39%
PLUR company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
36
Expensive
Momentum
29
Weakening
Sentiment
50
Mixed
Risk resilience
29
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websitePluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- IL
- CEO
- Yaacov Yanay
- Listed since
- Jun 30, 2003
- Employees
- 127
Market position
Day range
Current $1.71
52-week range
Current $1.71
- Open
- $1.70
- Previous close
- $1.77
- Volume
- 4.44K
- 0.21× average
- Average volume
- 21.49K
- Average daily volume
- Market cap
- 18.45M USD
- Beta
- 0.67
- Market reference 1
- 50-day average
- $1.8656
- -8.34% below average
- 200-day average
- $2.93
- -41.64% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 59.52M USD
- P/E (TTM)
- -0.6×
- P/B (TTM)
- -0.92×
- P/S (TTM)
- 17.1×
- EV / EBITDA
- -2.7×
- Earnings yield
- -71.99%
- Free cash flow yield
- -63.21%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 19.00%
- Operating margin
- -2412.14%
- Net margin
- -2424.75%
- Return on equity
- 330.06%
- Return on assets
- -58.38%
- Return on invested capital
- -64.63%
Financial health
- Debt / equity
- -1.81×
- Current ratio
- 0.68×
PLUR peers
Continue in GoAI
Research PLURresearch.disclaimer